Jeffrey L. Bennett

Active 1986–2025

105
Papers
19,019
Citations
66
h-index
97
i10-index

Citations

Citations per year for Jeffrey L. Bennett1986: 2 citations1988: 1 citations2000: 1 citations2001: 2 citations2002: 5 citations2003: 1 citations2004: 2 citations2005: 2 citations2006: 3 citations2007: 4 citations2008: 12 citations2009: 20 citations2010: 52 citations2011: 86 citations2012: 111 citations2013: 142 citations2014: 102 citations2015: 113 citations2016: 142 citations2017: 140 citations2018: 147 citations2019: 598 citations2020: 782 citations2021: 761 citations2022: 688 citations2023: 566 citations2024: 1,010 citations2025: 479 citations2026: 2 citations1987: no citations, so this year is not shown1989–1999: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 1,243 citing papers, 19.9% of this breakdownGermany: 578 citing papers, 9.2% of this breakdownUnited Kingdom: 486 citing papers, 7.8% of this breakdownChina: 441 citing papers, 7.1% of this breakdownItaly: 353 citing papers, 5.6% of this breakdownFrance: 253 citing papers, 4% of this breakdownJapan: 249 citing papers, 4% of this breakdownCanada: 193 citing papers, 3.1% of this breakdownSpain: 185 citing papers, 3% of this breakdownSwitzerland: 177 citing papers, 2.8% of this breakdownNetherlands: 176 citing papers, 2.8% of this breakdownAustria: 174 citing papers, 2.8% of this breakdown
0%19.9%Other 27.9%

Fields

  • Medicine80.4%
  • Neuroscience7.7%
  • Biochemistry, Genetics and Molecular Biology6.2%
  • Immunology and Microbiology4.3%
  • Engineering0.3%
  • Chemistry0.2%
  • Other0.9%

Topics

  • Multiple Sclerosis Research Studies19.9%
  • Peripheral Neuropathies and Disorders11.6%
  • Autoimmune Neurological Disorders and Treatments4.3%
  • Systemic Lupus Erythematosus Research3.9%
  • Neuroinflammation and Neurodegeneration Mechanisms3.8%
  • T-cell and B-cell Immunology2.1%
  • Other54.4%

Coauthors

All papers

Open in search
  1. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders

    Authors: , , , , , , , , , , , , , , , , , , - Neurology 2015 cited by 4,543

  2. Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria

    Authors: , , , , , , , , , , , , , , , , , , , , , , - The Lancet Neurology 2023 cited by 1,130

  3. Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial

    Authors: , , , , , , , , , , , , , , , , , , , , - The Lancet 2019 cited by 717

  4. Myelin-oligodendrocyte glycoprotein antibody-associated disease

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Krzysztof Selmaj, Aksel Sıva, Bruno Stankoff, Mar Tintoré, Anthony Traboulsee, Patrick Waters, Emmanuelle Waubant, Brian G. Weinshenker, Tobias Derfuß, Sandra Vukusic, Bernhard Hemmer - The Lancet Neurology 2021 cited by 517

  5. A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , - Neurology 2009 cited by 856

  6. Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial

    Authors: , , , , , , , , , , , , - The Lancet Neurology 2020 cited by 490

  7. Ravulizumab in Aquaporin‐4–Positive Neuromyelitis Optica Spectrum Disorder

    Authors: , , , , , , , , , , , , , , - Annals of Neurology 2023 cited by 191

  8. Interleukin-6 in neuromyelitis optica spectrum disorder pathophysiology

    Authors: , , , , , , , , - Neurology Neuroimmunology & Neuroinflammation 2020 cited by 246

  9. Optic neuritis and autoimmune optic neuropathies: advances in diagnosis and treatment

    Authors: , , , , , , - The Lancet Neurology 2022 cited by 202

  10. Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder (TANGO): an open-label, multicentre, randomised, phase 2 trial

    Authors: , , , , , , , , , , , , , , , - The Lancet Neurology 2020 cited by 272

  11. Myelin Oligodendrocyte Glycoprotein Antibody–Positive Optic Neuritis: Clinical Characteristics, Radiologic Clues, and Outcome

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , - American Journal of Ophthalmology 2018 cited by 400

  12. Emerging Cerebrospinal Fluid Biomarkers of Disease Activity and Progression in Multiple Sclerosis

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Ann Herman, Christopher Harp, Amit Bar‐Or - JAMA Neurology 2024 cited by 92

  13. International Delphi Consensus on the Management of AQP4-IgG+ NMOSD

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , - Neurology Neuroimmunology & Neuroinflammation 2023 cited by 86

  14. MRI characteristics of neuromyelitis optica spectrum disorder

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Dean Wingerchuk, Ho Jin Kim, Lekha Pandit, Ilya Kister, Maria Isabel Leite, Jacqueline Palace, Metha Apiwattanakul, Ingo Kleiter, Naraporn Prayoonwiwat, May Han, Kerstin Hellwig, Brenda Banwell, Katja Van Herle, Jacinta M. Behne, Gareth John, D. Craig Hooper, Kazuo Fujihara, Ichiro Nakashima, Douglas Kazutoshi Sato, Anthony Traboulsee, Michael R. Yeaman, Emmanuelle Waubant, Scott Zamvil, Jeffrey L. Bennett, Marco Aurélio Lana–Peixoto, Benjamin Greenberg, Olaf Stüve, Orhan Aktaş, Jens Wuerfel, Terry J. Smith, Nasrin Asgari, Anu Jacob, Kevin C. O’Connor - Neurology 2015 cited by 650

  15. Intrathecal pathogenic anti–aquaporin‐4 antibodies in early neuromyelitis optica

    Authors: , , , , , , , , , , , , , - Annals of Neurology 2009 cited by 586

  16. Serum Glial Fibrillary Acidic Protein: A Neuromyelitis Optica Spectrum Disorder Biomarker

    Authors: , , , , , , , - Annals of Neurology 2021 cited by 136

  17. Long-term Efficacy of Satralizumab in AQP4-IgG–Seropositive Neuromyelitis Optica Spectrum Disorder From SAkuraSky and SAkuraStar

    Authors: , , , , , , , , , , , - Neurology Neuroimmunology & Neuroinflammation 2022 cited by 66

  18. Treatment of MOG antibody associated disorders: results of an international survey.

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , M. Apiwattankul, Jyh Yung Hor, S Viswanathan, Wei Qiu, Han Jo Kim, Ichiro Nakashima, Kazuo Fujihara, Sudarshini Ramanathan, Russell C. Dale, M. Boggild, Simon Broadley, M. A. Lana-Peixoto, Douglas Kazutoshi Sato, Sílvia Tenembaum, P. Cabré, Dean M. Wingerchuk, Brian G. Weinshenker, Benjamin Greenberg, Marcelo Matiello, Eric C. Klawiter, Jeffrey L. Bennett, Asya I. Wallach, Ilya Kister, Brenda Banwell, Anthony Traboulsee, Daniela Pohl, Jacqueline Palace, Maria Isabel Leite, Michael Levy, Romain Marignier, Tom Solomon, Ming Lim, Saif Huda, A. Jacob - 2020 cited by 138

  19. Steroid-sparing maintenance immunotherapy for MOG-IgG associated disorder

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Hadas Stiebel‐Kalish, Sean J. Pittock - Neurology 2020 cited by 231

  20. Association of Maintenance Intravenous Immunoglobulin With Prevention of Relapse in Adult Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Julie Pique, Eoin P. Flanagan, Romain Marignier - JAMA Neurology 2022 cited by 112

  21. Differential effects of anti-CD20 therapy on CD4 and CD8 T cells and implication of CD20-expressing CD8 T cells in MS disease activity

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Christopher Harp, Ann Herman, Amit Bar‐Or - National Academy of Sciences, Proceedings of the National Academy of Sciences 2023 cited by 58

  22. Heterogeneity of Acetylcholine Receptor Autoantibody–Mediated Complement Activity in Patients With Myasthenia Gravis

    Authors: , , , , , , , , , - Neurology Neuroimmunology & Neuroinflammation 2022 cited by 56

  23. Concentration-dependent effects of CSF1R inhibitors on oligodendrocyte progenitor cells ex vivo and in vivo

    Authors: , , , , , - Experimental Neurology 2019 cited by 119

  24. Treatment of MOG-IgG-associated disorder with rituximab: An international study of 121 patients

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Rinze F. Neuteboom, Cheryl Hemingway, Rob Forsyth, Marcelo Matiello, Stewart Webb, David Hunt, Katy Murray, Yael Hacohen, Ming Lim, Maria Isabel Leite, Jacqueline Palace, Tom Solomon, Andreas Lutterotti, Kazuo Fujihara, Ichiro Nakashima, Jeffrey L. Bennett, Lekha Pandit, Tanuja Chitnis, Brian G. Weinshenker, Brigitte Wildemann, Douglas Kazutoshi Sato, Su‐Hyun Kim, Saif Huda, Ho Jin Kim, Markus Reindl, Michael Levy, Sven Jarius, Sílvia Tenembaum, Friedemann Paul, Sean J. Pittock, Romain Marignier, Anu Jacob - Multiple Sclerosis and Related Disorders 2020 cited by 179